Preclinical proof-of-concept studies have demonstrated that FLT3L treatment improves anti-tumor efficacy by enhancing T cell priming [32,33,34,35,36,37,38], providing a rationale for combining FLT3L therapy with T cell-directed CIT including checkpoint inhibition. The gene discussed is FLT3LG; the disease is neoplasm.